In March 2013, we announced plans to establish a new Global R&D Centre and Corporate Headquarters in Cambridge on the Cambridge Biomedical Campus, the future home to approximately 2,000 employees. In February 2015, Cambridge City Council granted planning permission for our new site.
AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.
Our skills focus on the discovery, development and commercialisation of medicines for the treatment of some of the world’s greatest healthcare challenges. Our commitment to making a meaningful difference in healthcare is founded on the pursuit of scientific excellence that addresses unmet patient need. Science is at the heart of AstraZeneca’s future strategy and success – and our aspiration is to achieve scientific leadership.
In March 2013, we announced our UK global R&D centre and corporate headquarters will be based at the Cambridge Biomedical Campus. The new, purpose-built site will be home to around 2000 highly-skilled staff, as part of our plan to create strategic global R&D centres in Britain, the United States and Sweden. This will bring together our small molecule and biologics activity, creating opportunities to capitalise on the promise of small and large molecule combinations, improving pipeline productivity and establishing AstraZeneca as a global leader in biopharmaceutical innovation.
The Biomedical Campus will also become our largest centre for oncology research, as well as hosting our work on cardiovascular and metabolic diseases, respiratory, inflammatory, autoimmune and nervous system conditions. Projects here will also include medicinal chemistry and high-throughput screening, and the facility will accommodate a number of pre-clinical research capabilities.
AstraZeneca has a long-standing presence in the UK and we're proud to be developing the next generation of medicines in Cambridge.

A global pharmaceutical company with a major UK presence. Through innovation and collaboration we can achieve better health for all.
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved EPANOVA (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridaemia (triglyceride levels greater than or equal to 500 mg/dL).
Pascal Soriot, AstraZeneca's Chief Executive Officer, commenting on Q1 2014 results, said: "The first quarter has seen continued momentum across the business and our revenue growth reflects the increasing contribution from the five growth platforms that showed strong performance.

AstraZeneca and the Medical Research Council (MRC) announced that they have entered into a groundbreaking collaboration aimed at better understanding the mechanisms of human disease. The collaboration will see the creation of a joint research facility at AstraZeneca’s new R&D centre in Cambridge in the UK.
AstraZeneca today announced a research collaboration with Shenzhen University Health Science Center. Under the agreement, the partners will undertake pre-clinical research focused on chronic kidney disease (CKD), which represents a large and growing unmet medical need in China. In 2010, there were over 112 million kidney disease sufferers in China and this is expected to rise by 20% to more...
AstraZeneca’s IMED Biotech unit has launched a dedicated website to support an increasing range of open innovation programmes and to better facilitate research collaborations with academia, industry, NGOs and governments.
AstraZeneca has announced the sale of its Alderley Park site in Cheshire, UK, to Manchester Science Parks (MSP), a Greater Manchester based public-private partnership and science park operator.
AstraZeneca has announced that it has entered into a collaboration with the Cancer Research UK (CRUK) Cambridge Institute to temporarily locate up to 60 AstraZeneca scientists in the Institute.
AstraZeneca announced that it has selected architects Herzog & de Meuron to design its new centre in Cambridge in the UK. The site, to be located on the Cambridge Biomedical Campus (CBC), will be home to one of three global strategic R&D centres and the company’s corporate headquarters, housing a highly-skilled workforce of approximately 2,000.
AstraZeneca announced its intention to establish a new global R&D centre and corporate headquarters in Cambridge in the UK by 2016.
Pages
There are no events to display

Data Provisioning Business Analyst
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Health Economics Manager (Oncology)
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Associate Director, Oncology R&D Communications
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Quality Assurance Associate
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Oncology Medical Training Leader
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Postdoc Fellow – Continuous Dehydrative Amide Formation
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Postdoc Fellow- Novel Methods for Data Collection and Analysis
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Postdoctoral Fellow - B-Cell Signatures of High-Affinity Antibodies
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Human Resources - Higher Apprenticeship
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Associate Director Clinical Scientist, Clinical Development
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

AstraZeneca Biometrics Graduate Programme: Statistics - UK
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Senior Scientist - Oncology Safety Sciences & Discovery
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Global Study Leader, Early Oncology Clinical
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Principal Statistician - Early Oncology
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Technician Scientist Microbiology Foundation Degree Apprenticeship
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Business Administrator Apprenticeship
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Laboratory Scientist Degree Apprenticeship
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Associate Director Physician - Early Oncology Clinical Development
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Health Economics and Payer Evidence Lead
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Group Associate Director - Study Operations Oncology
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Pages
No Blog articles found